Targeting of 4-1BB by monoclonal antibody PF-05082566 enhances T-cell function and promotes anti-tumor activity (Q39381907)

11 September 2017

Targeting of 4-1BB by monoclonal antibody PF-05082566 enhances T-cell function and promotes anti-tumor activity (English)

1 reference

11 September 2017

1 reference

1 reference

0 references

3

Theodore Oliphant

1 reference

11 September 2017

Timothy S Fisher

1

1 reference

11 September 2017

Cris Kamperschroer

2

1 reference

11 September 2017

Victoria A Love

4

1 reference

11 September 2017

Paul D Lira

5

1 reference

11 September 2017

Regis Doyonnas

6

1 reference

11 September 2017

Simon Bergqvist

7

1 reference

11 September 2017

Sangita M Baxi

8

1 reference

11 September 2017

Allison Rohner

9

1 reference

11 September 2017

Amy C Shen

10

1 reference

11 September 2017

Chunli Huang

11

1 reference

11 September 2017

Sharon A Sokolowski

12

1 reference

11 September 2017

Leslie L Sharp

13

1 reference

11 September 2017

11 March 2012

1 reference

Cancer Immunology, Immunotherapy

11 September 2017

1 reference

11 September 2017

61

1 reference

11 September 2017

10

1 reference

11 September 2017

1721-1733

1 reference

https://scigraph.springernature.com/pub.10.1007/s00262-012-1237-1

11 September 2017

0 references

cites work

Immune regulation by 4-1BB and 4-1BBL: complexities and challenges

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1237-1

Genes that distinguish physiological and pathological angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1237-1

4-1BB and OX40 act independently to facilitate robust CD8 and CD4 recall responses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1237-1

Three is better than one: pre-ligand receptor assembly in the regulation of TNF receptor signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1237-1

Serum levels of sCD137 (4-1BB) ligand are prognostic factors for progression in acute myeloid leukemia but not in non-Hodgkin's lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1237-1

ERK-dependent Bim modulation downstream of the 4-1BB-TRAF1 signaling axis is a critical mediator of CD8 T cell survival in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1237-1

The role of TNF superfamily members in T-cell function and diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1237-1

Immunobiology of cancer therapies targeting CD137 and B7-H1/PD-1 cosignal pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1237-1

The promise of 4-1BB (CD137)-mediated immunomodulation and the immunotherapy of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1237-1

Agonist anti-CD137 mAb act on tumor endothelial cells to enhance recruitment of activated T lymphocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1237-1

Dual immunoregulatory pathways of 4-1BB signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1237-1

Cytokine-mediated disruption of lymphocyte trafficking, hemopoiesis, and induction of lymphopenia, anemia, and thrombocytopenia in anti-CD137-treated mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1237-1

Intratumoral injection of interferon-α and systemic delivery of agonist anti-CD137 monoclonal antibodies synergize for immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1237-1

Clinical experiences with anti-CD137 and anti-PD1 therapeutic antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1237-1

Cloning, expression and characterization of monkey (Macaca fascicularis) CD137.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1237-1

A new Hu-PBL model for the study of human islet alloreactivity based on NOD-scid mice bearing a targeted mutation in the IL-2 receptor gamma chain gene.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1237-1

Development and homeostasis of T cell memory in rhesus macaque

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1237-1

Humanized mice in translational biomedical research

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1237-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1237-1

Cancer immunotherapy--revisited

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1237-1

Twelve immunotherapy drugs that could cure cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1237-1

A novel form of 4-1BBL has better immunomodulatory activity than an agonistic anti-4-1BB Ab without Ab-associated severe toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1237-1

Multivalent 4-1BB binding aptamers costimulate CD8+ T cells and inhibit tumor growth in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1237-1

Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1237-1

In vivo persistence, tumor localization, and antitumor activity of CAR-engineered T cells is enhanced by costimulatory signaling through CD137 (4-1BB)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1237-1

Activation of resting human primary T cells with chimeric receptors: costimulation from CD28, inducible costimulator, CD134, and CD137 in series with signals from the TCR zeta chain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1237-1

The promise and potential pitfalls of chimeric antigen receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1237-1

T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1237-1

Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1237-1

CD137 stimulation delivers an antigen-independent growth signal for T lymphocytes with memory phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1237-1

Immune modulation through 4-1BB enhances SIV vaccine protection in non-human primates against SIVmac251 challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1237-1

Inhibitory Fcγ receptor engagement drives adjuvant and anti-tumor activities of agonistic CD40 antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1237-1

Interaction with FcγRIIB is critical for the agonistic activity of anti-CD40 monoclonal antibody.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1237-1

Activation of human B cells by the agonist CD40 antibody CP-870,893 and augmentation with simultaneous toll-like receptor 9 stimulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1237-1

Immune modulation with weekly dosing of an agonist CD40 antibody in a phase I study of patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1237-1

CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1237-1

Defining the critical hurdles in cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1237-1

Levels of soluble CD137 are enhanced in sera of leukemia and lymphoma patients and are strongly associated with chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1237-1

10.1007/S00262-012-1237-1

21 January 2018

Identifiers

DOI

1 reference

11 September 2017

1 reference